Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × ARQ 197 × Sarcoma × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 7 Thoracic 3 Other solid neoplasm 2 Gastrointestinal 2 Sarcoma 1 Genitourinary 1 Dermatologic 1 Breast 1

Conditions

Sarcoma 1 Neoplasms 1

Interventions

Cyclophosphamide 58 Temozolomide 57 Radiotherapy 41 Doxorubicin 32 Filgrastim 25 Irinotecan 23 fludarabine 22 Radiation 21 Gemcitabine 20 Magnetic Resonance Spectroscopy 17 Etoposide 17 Imatinib Mesylate 16 Cisplatin 15 Carboplatin 15 pembrolizumab 14 Biopsy 14 Bevacizumab 14 fludarabine phosphate 13 Specimen Handling 13 Leucovorin 12 Granulocyte Colony-Stimulating Factor 12 pazopanib 11 Vincristine 11 Ifosfamide 11 Nivolumab 10 Melphalan 10 Ipilimumab 10 Erlotinib Hydrochloride 10 Chemotherapy, Adjuvant 10 Busulfan 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01468922 2022-07-01

Pazopanib and ARQ 197 for Advanced Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed

32 enrolled 21 charts

Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡